Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

post

Bergqvist P, Burke A, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2024

This poster describes AbCellera’s T-cell engager (TCE) platform, including tailored design strategies to generate optimized TCEs. A panel of novel CD3-binding antibodies are used to widen the therapeutic window by generating TCEs with potent tumor cell-killing and optimal cytokine release. Efficacy of molecules may be enhanced by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB. Finally, data is presented on the application of this platform to AbCellera’s B7-H4 and PSMA TCE programs, with preclinical characterization of TCEs showing tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks.

DOI: 10.1136/jitc-2024-SITC2024.1291

Download poster

Further reading:

  1. Lam K, et al. Cancer Res (2024) 84 (6_Supplement): 1859.
  2. de Puyraimond V, et al. Cancer Res (2024) 84 (6_Supplement): 6359.
  3. Mai M, et al. Cancer Res (2024) 84 (6_Supplement): 1868. 
  4. Mai M, et al. J Immunother Cancer 2023;11(Suppl 1):A1–A1731. 
  5. Mai M, et al. Cancer Res (2023) 83 (7_Supplement): 1886. 
  6. DeVorkin L, et al. Cancer Res (2022) 82 (12_Supplement): 312. 
  7. DeVorkin L, et al. J Immunother Cancer (2022)10 (Suppl 2):A1–A1603.